1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Arrys Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma grapiprant and pembrolizumab - Non-small Cell Lung Cancer Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Arrys Therapeutics | 18 | 2019-01-08 | 2021-02-21 |
| Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer grapiprant, grapiprant and pembrolizumab - Microsatellite Stable Colorectal Cancer | Phase 1 | Completed | Arrys Therapeutics | 54 | 2018-09-20 | 2023-10-24 |
grapiprant (2) · pembrolizumab (2)
United States (2)
Jason Sager, MD (1) · Sergio Santillana, MD (1)